Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bionomics Limited is an Australian clinical-stage biopharmaceutical company specializing in novel allosteric modulators of ion channels, primarily targeting the α7 nicotinic acetylcholine receptor for central nervous system disorders. Its lead product, BNC210, is an oral small molecule developed for anxiety and stress-related conditions like PTSD and social anxiety disorder. The company leverages ion channel biology expertise and partnerships to develop treatments addressing unmet medical needs in neuropsychiatric and cognitive disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.